Применение нестероидных противовоспалительных препаратов и генно-инженерных биологических препаратов для лечения аксиальных спондилоартритов. Рекомендации экспертной группы по изучению спондилоартритов при Общероссийской общественной организации "Ассоциация ревматологов России"

Автор: Гайдукова И.З., Ребров А.П., Лапшина С.А., Оттева Э.Н., Дубинина Т.В., Бадокин В.В., Бочкова А.Г., Бугрова О.В., Годзенко А.А., Дубиков А.И., Иванова О.Н., Коротаева Т.В., Несмеянова О.Б., Никишина И.П., Раскина Т.А., Румянцева О.А., Смирнов А.В., Ситало А.В., Эрдес Ш.Ф.

Журнал: Научно-практическая ревматология @journal-rsp

Рубрика: Международные и российские рекомендации по лечению ревматических заболеваний

Статья в выпуске: 5 т.55, 2017 года.

Бесплатный доступ

В статье представлены рекомендации по лекарственной терапии аксиальных спондилоартритов, разработанные Экспертной группой по изучению спондилоартритов (ЭкСпА). Рекомендации описывают тактику ведения пациентов в наиболее частых клинических ситуациях, направленную на обеспечение максимальной эффективности и безопасности лечения.

Спондилоартриты, аксиальные спондилоартриты, анкилозирующий спондилит, болезнь бехтерева, нестероидные противовоспалительные препараты, ингибиторы фактора некроза опухоли а, tumor necrosis factor-а inhibitors, ингибиторы интерлейкина 17, безопасность терапии

Еще

Короткий адрес: https://readera.org/14945850

IDR: 14945850   |   DOI: 10.14412/1995-4484-2017-474-484

Список литературы Применение нестероидных противовоспалительных препаратов и генно-инженерных биологических препаратов для лечения аксиальных спондилоартритов. Рекомендации экспертной группы по изучению спондилоартритов при Общероссийской общественной организации "Ассоциация ревматологов России"

  • Эрдес ШФ, Бадокин ВВ, Бочкова АГидр. О терминологии спондилоартритов. Научно-практическая ревматология. 2015; 53(6): 657-60
  • Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009; 68: 777-83 DOI: 10.1136/ard.2009.108233
  • Schoels MM, Braun J, Dougados M, et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis. 2014; 73(1): 238-42 DOI: 10.1136/annrheumdis-2013-203860
  • Gonzalez-Alvaro I, Martinez-Fernandez C, Dorantes-Calderon B, et al. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Rheumatology (Oxford). 2015 Jul; 54(7): 1200-9 DOI: 10.1093/rheumatology/keu461
  • Ward MM. Update on the American College of Rheumatology/Spondyloarthritis Research and Treatment Network/Spondylitis Association of America axial spondyloarhtritis treatment guidelines project. Clin Rheumatol. 2014; 33(6): 739-40 DOI: 10.1007/s10067-014-2660-9
  • Smolen JS, Schö ls M, Braun J, et al. Treating axial spondy-loarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2017 Jul 6 DOI: 10.1136/annrheumdis-2017-211734
  • Van der Heijde D, Sieper J, Maksymowych WP, et al; Assessment of SpondyloArthritis International Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011; 70(6): 905-8 DOI: 10.1136/ard.2011.151563
  • Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 DOI: 10.1136/annrheumdis-2016-210770
  • Гайдукова ИЗ, Ребров АП, Шувалова АА. Ремиссия при анкилозирующем спондилите и аксиальных спондилоартритах: современное понимание проблемы. Современная ревматология. 2016; 10(1): 48-51
  • Poddubnyy D, Gensler LS. Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. Best Pract Res Clin Rheumatol. 2014; 28(5): 807-18 DOI: 10.1016/j.berh.2014.10.005
  • Sieper J. How to define remission in ankylosing spondylitis? Ann Rheum Dis. 2012; 71 Suppl 2: i93-5 DOI: 10.1136/annrheumdis-2011-200798
  • Braun J, Kiltz U, Sarholz M, et al. Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes. Expert Rev Clin Immunol. 2015: 1-12 DOI: 10.1586/1744666X.2015.1052795
  • Гайдукова ИЗ, Ребров АП, Оттева ЭН и др. Применение нестероидных противовоспалительных препаратов для лечения аксиальных спондилоартритов, включая анкилозирующий спондилит, мониторинг эффективности и безопасности (проект рекомендаций группы экспертов по диагностике и лечению спондилоартритов). Научно-практическая ревматология. 2016; 54(Прил 1): 67-74
  • Лапшина СА, Дубинина ТВ, Бадокин ВВидр. Ингибиторы фактора некроза опухоли а в лечении аксиальных спондилоартритов (включая анкилозирующий спондилит). Научно-практическая ревматология. 2016; 54(Прил 1): 75-9
  • Каратеев АЕ. Комментарий к статье И.З. Гайдуковой и соавт. «Применение нестероидных противовоспалительных препаратов для лечения аксиальных спондилоартритов, включая анкилозирующий спондилит, мониторинг эффективности и безопасности (проект рекомендаций группы экспертов по диагностике и лечению спондилоартритов)». Научно-практическая ревматология. 2016; 54(3): 367-9
  • Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of АS. Ann Rheum Dis. 2011; 70: 896-904 DOI: 10.1136/ard.2011.151027896
  • Poddubnyy D, Rudwaleit M, Haibel H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011 Aug; 70(8): 1369-74 DOI: 10.1136/ard.2010.145995
  • Poddubnyy D, Sieper J. Radiographic progression in ankylosing spondylitis/axial spondyloarthritis: how fast and how clinically meaningful? Curr Opin Rheumatol. 2012 Jul; 24(4): 363-9 DOI: 10.1097/B0R.0b013e328352b7bd
  • Inman WH. Non-steroidal anti-inflammatory drugs: assessment of risks. Eur J Rheumatol Inflamm. 1987; 8(1): 71-85.
  • Bennett N, McGonagle D, O’Connor P, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum. 2008; 58(11): 3413-8 DOI: 10.1002/art.24024
  • Burd TA, Hughes MS, Anglen JO. Heterotopic ossifi cation prophylaxis with indomethacin increases the risk of long-bone nonunion. J Bone Joint Surg Br. 2003; 85: 700-5 DOI: 10.1302/0301-620X.85B5.13970
  • Bhattacharyya T, Levin R, Vrahas MS, et al. Nonsteroidal antiinfl ammatory drugs and nonunion of humeral shaft fractures. Arthritis Rheum. 2005; 53: 364-7. Научно-практическая ревматология. 2017; 55(5): 474-484 DOI: 10.1002/art.21170
  • Persson PE, Nilsson OS, Berggren AM. Do non-steroidal anti-infl ammatory drugs cause endoprosthetic loosening? A 10-year follow-up of a randomized trial on ibuprofen for prevention of heterotopic ossification after hip arthroplasty. Acta Orthop. 2005; 76: 735-40 DOI: 10.1080/17453670510045309
  • Gensler L, Reveille J, Lee M, et al. High dose nonsteroidal AntiInflammatory drugs (NSAIDs) and tumor necrosis factor Inhibitor Use results in less radiographic progression in Ankylosing Spondylitis -a Longitudinal Analysis . Arthritis Rheum. 2016; 68 Suppl 10: 2481-2.
  • Baraliakos X, Braun J. Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? RMD Open. 2015; 1 Suppl 1: e000053 DOI: 10.1136/rmdopen-2015-000053
  • Эрдес ШФ, Дубинина ТВ, Румянцева ОА и др. Эволюция аксиального спондилоартрита за 12 месяцев наблюдения когорты КоРСаР. Научно-практическая ревматология. 2016; 54(Прил 1): 55-9
  • Каратеев АЕ, Насонов ЕЛ, Яхно ННидр. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015; (1): 4-23
  • Malfertheiner P, Megraud F, O’Morain CA, et al; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 Jan; 66(1): 6-30 DOI: 10.1136/gutjnl-2016-312288
  • Chan FK, Graham DY. Review article: prevention of nonsteroidal anti-inflammatory drug gastrointestinal complications -review and recommendations based on risk assessment. Aliment Pharmacol Ther. 2004; 19(10): 1051-61 DOI: 10.1136/ard.2010.128660
  • Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther. 2004; 19(2): 197-208 DOI: 10.1111/j.1365-2125.2007.03038
  • Kono Y, Okada H, Takenaka R, et al. Does Helicobacter pylori exacerbate gastric mucosal injury in users of nonsteroidal antiinflammatory drugs? A multicenter, retrospective, case-control study. Gut Liver. 2016 Jan; 10(1): 69-75 DOI: 10.5009/gnl14372
  • Sostres C, Jerusalen Gargallo C, Lanas A. Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: Old question new insights. World J Gastroenterol. 2014; 20(28): 9439-50 DOI: 10.3748/wjg.v20.i28.9439
  • Greenland P, Alpert JS, Beller GA, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Circulation. 2010; 2010(122): e584-e636 DOI: 10.1016/j.jacc.2013.11.005
  • Orford JL, Sesso HD, Stedman MA, et al. Comparison of the Framingham and European Society of Cardiology coronary heart disease risk prediction models in the normative aging study. Am Heart J. 2002 Jul; 144(1): 95-100 DOI: 10.1067/mhj.2002.123317
  • Tsai WC, Ou TT, Yen JH, et al. Long-term frequent use of nonsteroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study. PLoS One. 2015; 10(5): e0126347. eCollection 2015 DOI: 10.1371/journal.pone.0126347
  • Ikdahl E, Rollefstad S, Olsen IC, et al. EULAR task force recommendations on annual cardiovascular risk assessment for patients with rheumatoid arthritis: an audit of the success of implementation in a rheumatology outpatient clinic. Biomed Res Int. 2015; 2015: 515280 DOI: 10.1155/2015/515280
  • Heslinga SC, van den Oever IA, van Sijl AM, et al. Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation. BMC Musculoskelet Disord. 2015; 16: 80 DOI: 10.1186/s12891-015-0532-3
  • Rafaniello C, Ferrajolo C, Sullo MG, et al. Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system. Pharmacol Res. 2015 Dec 29; 104: 108-14 DOI: 10.1016/j.phrs.2015.12.026
  • Rosen E, Tsesis I, Vered M. . Refuat Hapeh Vehashinayim. 1993; 32(4): 6-10.
  • Hsu CC, Wang H, Hsu YH, et al. Use of Nonsteroidal AntiInflammatory Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension: Nationwide Longitudinal Cohort Study. Hypertension. 2015 Sep; 66(3): 524-33 DOI: 10.1161/hyper-tensionaha.114.05105
  • Ingrasciotta Y, Sultana J, Giorgianni F, et al. Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study. PLoS One. 2015 Apr 16; 10(4): e0122899. eCollection 2015 DOI: 10.1371/journal.pone.0122899
  • Cao YL, Tian ZG, Wang F, et al. Characteristics and clinical outcome of nonsteroidal anti-inflammatory drug-induced acute hepato-nephrotoxicity among Chinese patients. World J Gastroenterol. 2014; 20(38): 13956-65 DOI: 10.3748/wjg.v20.i38.13956
  • Nderitu P, Doos L, Jones PW, et al. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013; 30(3): 247-55 DOI: 10.1177/2050640613502900
  • Pazhayattil GS, Shirali AC. Drug-induced impairment of renal function. Int J Nephrol Renovasc Dis. 2014; 7: 457-68 DOI: 10.2147/IJNRD.S39747
  • Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis. 2012; 71 Suppl 2; i2-45 DOI: 10.1136/ard.2010.144998
  • Rudwaleit M, van der Heijde D, Landewe R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondy-loarthritis in general. Ann Rheum Dis. 2011 Jan; 70(1): 25-31 DOI: 10.1136/ard.2010.133645
  • Lukas C, Landewe R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Assessment of SpondyloArthritis international Society. Ann Rheum Dis. 2009; 68(1): 18-24 DOI: 10.1136/ard.2008.094870
  • Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994; 21(12): 2286-91.
  • Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015 Apr 18; 4: CD005468 DOI: 10.1002/14651858.CD005468.pub2
  • Wu D, Guo YY, Xu NN, et al. Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis. BMC Musculoskelet Disord. 2015 Feb 10; 16: 19 DOI: 10.1186/s12891-015-0489-2
  • Mackay K, Brophy S, Mack C, et al. The development and validation of a radiographic grading system for the hip in Ankylosing Spondylitis: the Bath Ankylosing Spondylitis Radiology Hip Index. J Rheumatol. 2000; 27: 2866-72.
  • Резюме Совета экспертов «Вопросы "выживаемости" генноинженерных биологических препаратов и возможности переключения на секукинумаб при анкилозирующем спондилите в реальной клинической практике» Москва, 10 февраля 2017 г. Научно-практическая ревматология. 2017; 55(2): 230-1
  • Arends S, Lebbink HR, Spoorenberg A, et al. The formation of autoantibodies and antibodies to TNF-а blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol. 2010; 28(5): 661-8 DOI: 10.1186/ar3369
  • Plasencia C, Pascual-Salcedo D, Nuno L, et al. Influence of immunogenicity on the efficacy of longterm treatment of spondy-loarthritis with infliximab. Ann Rheum Dis. 2012; 71(12): 1955-60 DOI: 10.1136/annrheumdis-2011-200828
  • Murdaca G, Spano F, Contatore M, et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin Drug Saf. 2016; 15(1): 43-52 DOI: 10.1517/14740338.2016.1112375
  • Гайдукова ИЗ, Ребров АП, Апаркина АВ, Хондкарян ЭВ. Концентрация интерлейкина-17а остается стабильно высокой у больных анкилозирующим спондилитом, получающих ингибиторы фактора некроза опухоли а в течение года. Терапевтический архив. 2017; 89(4): 80-5
  • Cantini F, Niccoli L, Cassara E, et al. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-upstudy. Biologics. 2013; 7: 1-6 DOI: 10.2147/BTT.S31474
  • Arends S, van der Veer E, Kamps FB, et al. Patient-tailored dose reduction of TNF-а blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. Clin Exp Rheumatol. 2015; 33(2): 174-80.
  • Olivieri I, D’Angelo S, Padula A, et al. Can we reduce the dosage of biologics in spondyloarthritis? Autoimmun Rev. 2013 May; 12(7): 691-3 DOI: 10.1016/j.autrev.2012.08.013
  • Song IH, Haibel H, Poddubnyy D, et al. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease. Clin Exp Rheumatol. 2013 Jul-Aug; 31 4 Suppl 78: S37-42.
  • Spadaro A, Punzi L, Marchesoni A, et al. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology (Oxford). 2010; 49(6); 1107-11 DOI: 10.1016/S0140-6736(17)30068-5
  • Braun J, Sieper J. Remission and possible discontinuation of biological therapy in axial spondyloarthritis. Clin Exp Rheumatol. 2013; 31 Suppl 78: S33-6.
  • Hohenberger M, Cardwell LA, Oussedik E, et al. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat. 2017 May; 18: 1-23 DOI: 10.1080/09546634.2017.1329511
  • Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015 Dec 24; 373(26): 2534-48 DOI: 10.1056/NEJMoa1505066
  • Accortt NA, Bonafede MM, Collier DH, et al. Risk of subsequent infection among patients receiving tumor necrosis factor inhibitors and other disease-modifying antirheumatic drugs. Arthritis Rheum. 2016; 68(1): 67-76 DOI: 10.1002/art.39416
  • Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf 2016; 15 Supp1: 11-34 DOI: 10.1080/14740338.2016.1240783
  • Ooka K, Lim JK. Treatment of hepatitis C in patients undergoing immunosuppressive drug therapy. J Clin Transl Hepatol. 2016 Sep 28; 4(3): 206-27 DOI: 10.14218/JCTH.2016.00017
  • Valaydon Z, Pellegrini M, Thompson A, et al. The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde. Clin Transl Immunol. 2016; 5(12): e115 DOI: 10.1038/cti.2016.68
  • Белов БС. Терапия генно-инженерными биологическими препаратами и инфекции у больных ревматоидным артритом: актуальность и перспективы. Научно-практическая ревматология. 2014; 52(3): 322-30
  • Wangsiricharoen S, Ligon C, Gedmintas L, et al. The rates of serious infections in HIV-infected patients who received tumor necrosis factor (TNF)-a inhibitor therapy for concomitant autoimmune diseases. Arthritis Care Res (Hoboken). 2017; 69(3): 449-52 DOI: 10.1002/acr.22955
  • Aboulafia DM, Bundow D, Wilske K, Ocas UI. Etanercept for the Treatment of Human Immunodeficiency Virus-Associated Psoriatic Arthritis. Mayo Clin Proc. 2000; 75: 1093-8 DOI: 10.4065/75.10.1093
  • Mikhail M, Weinberg JM, Smith BL. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus. Arch Dermatol. 2008 Apr; 144(4): 453-6 DOI: 10.1001/archderm.144.4.453
  • Cepeda EJ, Williams FM, Ishimori MLet al. The use of antitumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis. 2008; 67: 710-2 DOI: 10.1136/ard.2007.081513
  • Gallitano SM, McDermott L, Brar K, Lowenstein E. Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS. J Am Acad Dermatol. 2016 May; 74(5): 974-80 DOI: 10.1016/j.jaad.2015.11.043
  • Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS. 2004; 18: 257-64 DOI: 10.1016/j.jaad.2015.11.043
  • Solomon DH, Mercer E, Kavanaugh A. Observational Studies on the Risk of Cancer Associated with TNF-Inhibitors in RA: A Review of their Methodologies and Results. Arthritis Rheum. 2012; 64(1): 21-32 DOI: 10.1002/art.30653
Еще
Статья научная